CHARMPreserved研究课件.pptVIP

下载本文档

3
0
约4.84千字
约 8页
2015-09-11 发布于重庆
举报
版权申诉

CHARMPreserved研究课件.ppt

1、本文档共8页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

CHARMPreserved研究课件,研究性学习课件,高中研究性学习课件,杠杆类工具的研究课件,基础教育改革研究课件,体育科学研究方法课件,学前教育研究方法课件,小学数学研究课件,丁丁的研究报告课件,研究透镜课件

CHARM-Preserved:Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin II receptor blocker candesartan is beneficial in patients with chronic heart failure (CHF) and preserved left ventricular systolic function Reference Yusuf S, Pfeffer MA, Swedberg K, et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777–81. CHARM-Preserved:Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved- TRIAL DESIGN - Design Multicenter, multinational, randomized, double-blind, placebo-controlled Patients 3023 patients aged 18 years with symptomatic CHF (NYHA class II–IV), who had left ventricular ejection fraction 40% Follow up and primary endpoint Primary endpoint: cardiovascular death or hospital admission for CHF. Median 36.6 months follow up. Treatment Placebo or candesartan titrated to 32 mg once daily CHARM-Preserved:Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved- TRIAL DESIGN continued- CHARM-Preserved:Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved- RESULTS - Nonsignificant trend to reduction in primary outcome of cardiovascular death or hospital admission for CHF in candesartan group compared with placebo (22 vs. 24.3%, P=0.118) Secondary outcomes – composites of primary outcome and MI, nonfatal stroke and coronary revascularization – also showed nonsignificant trend Total number of hospital admissions for CHF significantly reduced in candesartan group (402 vs. 566, P=0.014) All-cause mortality similar in both groups (244 vs. 237 patients) Permanent discontinuation due to adverse event or laboratory abnormality more frequent with candesartan (17.8 vs. 13.5%, P=0.001) CHARM-Preser